Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Changhai Hospital
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male and female participants aged 18-70 (including those who are 18 and 70 years old)；
2. Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1);
3. Life expectancy ≥ 12 weeks;
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
5. Adequate marrow and organ function;
You may not be if
1. Prior receipt of any anti-tumor therapy, including but not limited to systemic chemotherapy, radiotherapy, interventional therapy, immunotherapy, targeted therapy, and anti-tumor traditional Chinese medicine therapy;
2. Presence of distant metastatic lesions confirmed by imaging;
3. Known hypersensitivity to the investigational drug or any of its excipients;
4. Presence of any serious or uncontrolled systemic disease;
5. History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
6. Clinically significant acute or chronic pancreatitis;
7. Participation in any interventional clinical trial involving drugs or medical devices within 4 weeks prior to the first administration of study treatment;
8. Vaccination with live or live-attenuated vaccines within 4 weeks prior to the first dose of the investigational drug;
9. Any other condition that, in the judgment of the investigator, makes the subject unsuitable for enrollment.
Clareo Health | Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer
